NBE-P2
Alternative Names: New Biological Entity P2Latest Information Update: 08 Oct 2008
At a glance
- Originator Direvo Biotech
- Class Peptide hydrolases
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 22 Jun 2005 This programme is still in active development - (BIO-2005)
- 22 Mar 2004 Early research in Inflammation in Germany (unspecified route)